Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail takes on rare nerve tumors

NCT ID NCT05253131

Not yet recruiting Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This early-phase trial tests a combination of three drugs—selumetinib, ZEN-3694, and durvalumab—in people with advanced sarcomas, including malignant peripheral nerve sheath tumors (MPNST) linked to NF1. The study first checks safety and dosing, then looks at whether the treatment can shrink tumors or stop them from growing. About 41 adults will take part across multiple U.S. sites.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Selumetinib, ZEN-3694, and durvalumab
What this could lead to
If successful, this combination could offer a new treatment option for people with hard-to-treat sarcomas, especially those with NF1-related MPNST.
What could go wrong
This is an early-phase trial with only 41 participants. The drugs may cause serious side effects, and the benefit rate is uncertain—the study may stop early if no one responds.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND BLUE CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoplastic small round cell tumor Ewing sarcoma malignant peripheral nerve sheath tumor neurofibromatosis type 1 neurofibrosarcoma osteosarcoma rhabdomyosarcoma sarcoma synovial sarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MPNST NF1 SARCOMA

Contacts and locations

Locations

  • The University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.